Evoke Pharma

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

NiSun International Enterprise Development Group Co Ltd

Penny stocks to watch under $1 today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 To Watch Under $1 This Week

Evoke Pharma, Inc. EVOK Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants David Gonyer – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, EVERSANA Matthew D'Onofrio – Chief Business Officer Daniel Kontoh-Boateng – Investor Relations Conference Call Participants Yale Jen – Laidlaw and Company Mitchell Kapoor – H.C. Wainwright & Co., LLC Operator Please stand by.

Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q1 2022 Results - Earnings Call Transcript

Globalstar

IT Tech Packaging Inc

Kala Pharmaceuticals

Kiromic Biopharma

MEI Pharma

Pingtan Marine Enterprise

PolarityTE Inc

Sesen Bio Inc.

Sonim Technologies Inc

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes.

Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022

Camber Energy

Geovax Labs

Why these 3 penny stocks are climbing today The post 3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120%

Evoke Pharma is up an unbelievable 130% today on news of recently granted drug exclusivity. How high will EVOK stock soar?

Why Is Evoke Pharma (EVOK) Stock Up 130% Today?

The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults. Evoke now has exclusive marketing rights over three (3) years.

Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray

Evoke Pharma, Inc. (EVOK) CEO Dave Gonyer on Q4 2021 Results - Earnings Call Transcript

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3  Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare professionals

Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2021 financial results on Tuesday, March 8, 2022, after the market closes.

Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study

Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022

SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Services, LLC, an independent provider of global commercial services to the life science industry, today announced the extension of their agreement to continue collaborating on the commercialization and distribution of Gimoti® (metoclopramide) nasal spray in the United States through the end of 2026.

Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

Evoke Pharma's (EVOK) CEO Dave Gonyer on Q3 2021 Results - Earnings Call Transcript

SOLANA BEACH, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the quarter ended September 30, 2021 and recent corporate developments.

Evoke Pharma Reports Third Quarter 2021 Financial Results

SOLANA BEACH, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its third quarter 2021 financial results on Wednesday, November 10, 2021, after the market closes.

Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021

Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis

Evoke Pharma's Commercial Partner EVERSANA, Receives PM360's Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI

SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D'Onofrio, Chief Business Officer, will participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 – 15, 2021.

Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

The shares of Evoke Pharma, Inc. (NASDAQ: EVOK) increased by over 10% pre-market. This is why it happened.

Evoke Pharma Shares Increase Over 10% Pre-Market: Why It Happened

Evoke Pharma Inc (NASDAQ: EVOK) shares are trading higher by 23.1% at $1.38 after the company reported better-than-expected second-quarter EPS results. Evoke Pharma reported quarterly losses of 7 cents per share which beat the analyst consensus estimate of a loss of 8 cents per share.

What's Up With Evoke Pharma's Stock Popping Off Friday?

The shares of Evoke Pharma, Inc. (NASDAQ: EVOK) fell by over 12% pre-market. This is why it happened.

Evoke Pharma Shares Fell Over 12% Pre-Market: Why It Happened

Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2021 Results - Earnings Call Transcript

Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ®

Evoke Pharma Reports Second Quarter 2021 Financial Results

Participating and Sponsorship in Upcoming Digestive Health Virtual Walk Participating and Sponsorship in Upcoming Digestive Health Virtual Walk

Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders' (IFFGD) August Gastroparesis Awareness Month

Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers

Evoke Pharma Launches Gimoti® Patient and Physician Experience Program

Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk

News for Evoke Pharma Stock (EVOK)